Chronic activation of a designer G(q)-coupled receptor improves β cell function

Area of Science:

• Endocrinology
• Metabolic Diseases
• Molecular Biology

Background:

• Type 2 diabetes (T2D) is a global health concern.
• Improving pancreatic beta cell function is a key therapeutic goal for T2D.
• Existing T2D treatments have limitations.

Purpose of the Study:

• To investigate the therapeutic potential of activating G(q) signaling in pancreatic beta cells.
• To identify molecular pathways involved in G(q) signaling in beta cells.
• To assess the efficacy of targeting G(q) signaling for T2D treatment.

Main Methods:

• Utilized in vivo and in vitro models in mice.
• Employed drug-mediated, chronic, and selective activation of beta cell G(q) signaling.
• Analyzed gene expression critical for beta cell function, maintenance, and differentiation.
• Investigated the sequential activation of ERK1/2 and IRS2 signaling pathways.

Main Results:

• Chronic activation of beta cell G(q) signaling significantly improved beta cell function and glucose homeostasis in mice.
• Enhanced expression of key genes involved in beta cell function, maintenance, and differentiation was observed.
• A novel pathway involving G(q) -> ERK1/2 -> IRS2 signaling was identified.
• Targeted G(q) receptor stimulation prevented streptozotocin-induced diabetes and high-fat diet-induced metabolic deficits.

Conclusions:

• Drug-mediated activation of beta cell G(q) signaling represents a promising therapeutic strategy for type 2 diabetes.
• The identified G(q)-ERK1/2-IRS2 pathway is crucial for maintaining beta cell function.
• Targeting G(q)-coupled receptors in beta cells offers a rational approach for novel antidiabetic drug development.